Only way is up.., page-373

Meaning this...
I didn't notice this at all.
Maybe out the window with Boaz ?
Imo if it was still on the table surely there would have been more of a mention ?
Suprise maybe ? haha.

Good find though

http://www.abnnewswire.net/press/en/79467/



Couldn't find much more.


http://www.resourcesroadhouse.com.a...al-signs-medical-cannabis-heads-of-agreement/


Monday, March 02, 2015
THE ROADHOUSE PHARMACY: Australian Medical Grade Cannabis (MGC) company, Phytotech Medical Limited (ASX: PYL) has entered into a Heads of Agreement with Israel-based Canigma A.L. Ltd to develop a revolutionary capsule based vaporiser to administer medical cannabis.

Canigma holds a number of intellectual property interests pertaining to a vaporiser delivery devices for medical cannabis.

Under this agreement, Phytotech will fund development of the application, which is the subject of the Agreement, with the purpose of commercialising the product.

Phytotech explained the funding it is to provide will be put towards the granting process of a patent for the device, the proof of concept and the development of the prototype.

The device to be developed is a capsule based vaporiser with a unique and innovative delivery method for administering MGC.

The product, which is patent pending at this stage, will offer an all in one product, with ready to use cannabis capsules.

The company claims the capsule provides minimal contact between the consumer and the raw material and will be focused on increasing the efficiency, above the industry standard, through conduction and convection heating technologies.

Phytotech declared its innovative delivery method will provide patients with a clean, measurable and constant experience.

The Canigma device capsule strategy is based on the ‘Nespresso’ model with the intention being dispensaries will stock different capsules to treat different indications and doctors will then provide prescriptions to patients for a MGC capsule that has a defined ratio of THC and CBD.

The desire is that this will prevent abuse of the system while allowing doctors to monitor the use of MGC by patients more closely.

“This agreement marks an important milestone in our business strategy,” Phytotech Medical managing director Boaz Wachtel said in the company’s announcement to the Australian Securities Exchange.

“We’re delighted to be partnering with Canigma on the development of this revolutionary product and through this important phase for our business.

“The use of cannabis capsules in a vaporiser is set to be the first product of its kind in the market and will bring substantial health benefits to the user.

“The team at Canigma bring the necessary skills and expertise required to successfully execute the development of this product and we look forward to working together to bring the vaporiser to market.”